StockDrifts LogoStockDrifts

Aimed Bio 0009K0

Company
에임드바이오Aimed Bio
Insiders
1
Buys
0
Total Value
₩143.5B ($99.6M)
Avg Return
+13.28%
Last Filing
2026-03-16

Aimed Bio (0009K0) has 0 disclosed insider purchases and 6 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩143.5B ($99.6M) in reported transaction value. The earliest filing StockDrifts holds for Aimed Bio is dated 2025-12-04; the most recent is 2026-03-16. Across these filings the average return since disclosure is +13.28%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-09-11BUY주식매수선택권
안선희
Seonhee Ahn
moving15.0K₩22,650-4.4%₩340M ($236K)
2026-03-16SELLMarket Sell
인터베스트
Intervest
--67.1K₩64,300+17.3%₩4.3B ($3.0M)
2026-03-13SELLMarket Sell
인터베스트
Intervest
--80.0K₩69,400+23.3%₩5.6B ($3.9M)
2026-03-12SELLMarket Sell
인터베스트
Intervest
--650.0K₩70,300+24.3%₩45.7B ($31.7M)
2026-03-11SELLMarket Sell
인터베스트
Intervest
--500.0K₩65,100+18.3%₩32.5B ($22.6M)
2026-03-10SELLMarket Sell
인터베스트
Intervest
--450.0K₩64,400+17.4%₩29.0B ($20.1M)
2026-02-04SELL시간외매매
인터베스트
Intervest
--1.0M₩55,600+4.3%₩55.6B ($38.6M)
2026-01-02BUY주식매수선택권
허남구
Heonam-gu
CEO65.0K₩54,700-2.7%₩3.6B ($2.5M)
2026-01-02BUY주식매수선택권
민병귀
Min Byeong-gwi
Director of Research Institute50.0K₩54,700-2.7%₩2.7B ($1.9M)
2026-01-02BUY주식매수선택권
김태경
Taekyung Kim
COO85.0K₩54,700-2.7%₩4.6B ($3.2M)
2026-01-02BUY주식매수선택권
김미현
Mihyeon Kim
moving30.0K₩54,700-2.7%₩1.6B ($1.1M)
2026-01-02BUY주식매수선택권
안선희
Seonhee Ahn
moving20.0K₩54,700-2.7%₩1.1B ($760K)
2025-12-04SELLMarket Sell
인터베스트
Intervest
--600.0K₩44,000-20.9%₩26.4B ($18.3M)
2025-12-04BUY신규상장
남도현
Nam Dohyun
CTO22.2M₩44,000+20.9%₩975.2B ($677.3M)
2025-12-04BUY신규상장
인터베스트
Intervest
-10.2M₩44,000+20.9%₩448.6B ($311.5M)

Frequently asked questions

Who has been buying Aimed Bio stock?
1 distinct insiders have filed 0 disclosed insider purchases in Aimed Bio (0009K0), most recently on 2026-03-16. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Aimed Bio have?
Aimed Bio has 0 buy-side and 6 sell-side disclosures on record, covering ₩143.5B ($99.6M) in total reported value, spanning 2025-12-04 to 2026-03-16.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse the Korean stocks we cover.

Related Korean stocks